Excellent efficacy in various preclinical animal models
LUCID-MS
| Idea/Target | Lead | In vivo PoC | IND Enabling Studies | Phase 1 | Phase 2 | Phase 3 | Launch | |
|---|---|---|---|---|---|---|---|---|
| LUCID-MS |  Multiple sclerosis |
Phase 1 SAD/MAD Human Studies Completed | ||||||
LUCID-21-302 Opportunity Assessment and Commercialization Plan: Final Report
November 2022
How Lucid-MS Works:
Addressing Demyelination
Patented new chemical entity (NCE)
Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions. Lucid-MS has shown excellent results in several animal models, as demonstrated in the video below.
LUCID-MS: Disease Modifying Enabling Remyelination
The subject in the video above is only one example taken from a large cohort of mice in experiments conducted in multiple labs across several years. The results of the preclinical research from these experiments has been published in various prestigous medical journals, including Journal of Medicinal Chemistry and Proceedings of the National Academy of Sciences (PNAS). Lucid-MS is a patented (patent #WO2017027967A1) New Chemical Entity (NCE) that has been studied extensively throughout more than 11 years of research and development. Quantum BioPharma owns exclusive worldwide rights to Lucid-MS.
Quantum BioPharma Dr. Andrzej Chruscinski On Recent Multiple Sclerosis Trial Breakthroughs
Dr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma
Multiple Sclerosis breakthrough - FSD Pharma
A sampling of the novel qualities of Lucid-MS include:
Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
Does not suppress immune system (non-immunomodulatory)
Potential oral administration with easy dosing regimen
Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.
Today there is no cure for Multiple Sclerosis.
Quantum BioPharma (“QNTM”) is trying to change this for millions of people.
Multiple Sclerosis Overview
Estimated Diagnosed MS Patients by Region
A chronic inflammatory and degenerative disorder of the central nervous system, Multiple Sclerosis (MS) continues to affect a growing global population. Global prevalence of MS rose from approximately 2.3 million people in 2013 to 2.8 million in 2020, and approximately 2.9 million people in 2023.
MS is characterized by unpredictable symptoms, including tingling sensations, vision problems, fatigue, pain, mobility issues, bladder or bowel dysfunction, and cognitive changes. These symptoms are associated with the patient’s immune system attacking myelin and nerve fibers within the central nervous system.
Damage to myelin, the protective sheath surrounding nerve fibers, can disrupt communication between the brain, spinal cord, optic nerves, and the rest of the body, potentially affecting mobility, vision, sensation, and cognitive function.
MS can occur at any age, although the average age of diagnosis globally is approximately 32 years. Globally, females are at least twice as likely as males to be diagnosed with MS.
In the United States, nearly 1 million people are living with MS. In Canada, more than 90,000 people are living with MS, and the Public Health Agency of Canada reports approximately 290 cases per 100,000 adults aged 20 years and older.
Australia also represents a meaningful MS population. According to MS Australia’s 2025 report, approximately 37,756 people were living with MS in Australia in 2024, equal to 139.2 cases per 100,000 people. Of these, 23,217 people, or 62%, were using disease-modifying therapies.
Europe remains one of the major global MS regions, with available regional estimates showing approximately 543,862 diagnosed MS patients in Western Europe and approximately 204,591 diagnosed MS patients in Central and Eastern Europe.
Across Asia, MS prevalence varies significantly by country, but available regional estimates include approximately 103,194 diagnosed MS patients in China and approximately 46,249 diagnosed MS patients in Japan.
In the United Arab Emirates and the wider Gulf region, MS is increasingly recognized, with published UAE estimates reporting overall prevalence around 18–19 cases per 100,000 people, and higher reported prevalence among Emiratis in Abu Dhabi.
The global multiple sclerosis therapeutics market remains significant. Precedence Research estimates the market at approximately US$34.8 billion in 2025 and projects it could reach approximately US$66.8 billion by 2035.
Sources: Atlas of MS / MSIF, 2023 update; National Multiple Sclerosis Society, U.S. prevalence; Public Health Agency of Canada, Multiple Sclerosis in Canada, 2024; MS Canada; MS Australia, Multiple Sclerosis Prevalence and Health Economic Impact in Australia 2025; Precedence Research, Multiple Sclerosis Therapeutics Market; Clene Inc. Corporate Presentation, SEC Exhibit 99.2, September 17, 2021; National MS Society UAE Baseline Survey; Schiess et al. UAE prevalence studies.
Source Links: Sources
[1] Atlas of MS / Multiple Sclerosis International Federation (MSIF) — 2023 Update
Used for global MS prevalence: approximately 2.3 million people in 2013, 2.8 million in 2020, and 2.9 million in 2023. Also used for global average diagnosis age and female-to-male diagnosis ratio.
https://atlasofms.org/
[2] National Multiple Sclerosis Society — U.S. MS Prevalence
Used for the United States estimate of nearly 1 million people living with MS.
https://www.nationalmssociety.org/about-the-society/who-we-are/research-we-fund/ms-prevalence
[3] Public Health Agency of Canada / MS Canada — Canadian MS Prevalence
Used for Canada’s MS prevalence figures, including more than 90,000 Canadians living with MS and approximately 290 cases per 100,000 adults aged 20 years and older.
https://www.canada.ca/en/public-health/services/publications/diseases-conditions/multiple-sclerosis-infographic.html
https://mscanada.ca/ms-research/latest-research/prevalence-and-incidence-of-ms-in-canada-and-around-the-world
[4] MS Australia — Multiple Sclerosis Prevalence and Health Economic Impact in Australia 2025
Used for Australia’s 2024 figures: 37,756 people living with MS, 139.2 cases per 100,000 people, and 23,217 people using disease-modifying therapies.
https://www.msaustralia.org.au/wp-content/uploads/ms-prevalence-and-health-economic-impact-in-australia-2025_web.pdf
[5] Precedence Research — Multiple Sclerosis Therapeutics Market
Used for the global MS therapeutics market estimate of approximately US$34.8 billion in 2025 and projected market size of approximately US$66.8 billion by 2035.
https://www.precedenceresearch.com/multiple-sclerosis-therapeutics-market
[6] Clene Inc. Corporate Presentation — SEC Exhibit 99.2, September 17, 2021
Used only for selected contextual regional diagnosed-patient estimates: Western Europe, Central/Eastern Europe, China, and Japan.
https://www.sec.gov/Archives/edgar/data/1822791/000121390021048457/ea147546ex99-2_cleneinc.htm
[7] National MS Society UAE / Schiess et al. UAE MS Prevalence Studies
Used for UAE prevalence estimates, including approximately 18–19 cases per 100,000 people overall and approximately 64.4 cases per 100,000 age-standardized prevalence among Abu Dhabi Emiratis.
https://www.nationalmssociety.ae/uploads/240517_nmss_baseline-survey-report-en.pdf
https://www.msard-journal.com/article/S2211-0348(16)30106-7/pdf
Source Note: Selected Europe and Asia figures are regional diagnosed-patient estimates from a cited corporate presentation and are provided for contextual reference only.
Disclaimer: Figures are sourced from third-party epidemiology, public health, corporate presentation, and market research sources. Estimates may vary by methodology, geography, year, diagnostic criteria, and data availability. Market-size figures are third-party estimates and should not be interpreted as Quantum BioPharma guidance or projections.
Armed with a strong balance sheet, solid pipeline, and renowned clinical team, Quantum BioPharma intends to advance its lead drug candidate through clinical trials with the goal of providing therapies to the millions suffering from neurodegenerative conditions such as Multiple Sclerosis. We want to see Lucid-MS help those with these conditions, as we advance science, and save lives.
Today there is no cure for Multiple Sclerosis (MS). Quantum BioPharma will attempt to change that for millions of suffering people. Quantum BioPharma’s proprietary compound Lucid-MS has shown promising results to reverse progressive MS, in several animal models
Well positioned to advance current pipeline and aggressively pursue additional acquisitions that present compelling opportunities across the innovative biotech space focused on “Total Brain Health”
Renowned scientific team includes Dr. Lakshmi P. Kotra, recipient of the Julia Levy Award and Senior Scientist at the Krembil Brain Institute and University Health Network (UHN). Dr. Kotra is also a Professor of Medicinal Chemistry at the University of Toronto and serves as a Senior Advisor to Quantum BioPharma.
Learn about Multiple Sclerosis Facts
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that affects the brain and spinal cord. It is characterized by inflammation, demyelination and degeneration of the CNS. MS progresses in various stages, and the clinical course can vary widely among individuals.
